Neuren receives FDA approval
Posted: 23 March 2022 BioMelbourne Network Member, Neuren Pharmaceuticals, has received approval from the US Food and Drug Administration (FDA) to proceed with the Phase 2 trial of NNZ-2591 in PhelanMcDermid syndrome (PMS). The Investigational New Drug application…
Technovalia, Sypharma and BioNet announce Australian Vaccine Hub
Posted: 23 March 2022 Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines. Establishment of the first end-to-end Australian capability for product development and…
New national agency to advance genomic medicine welcomed
Posted: 22 March 2022 Australian Genomics Lead Professor Kathryn North says a new national agency to support genomic medicine will help propel the integration of genomics into mainstream healthcare, a transformative approach to patient diagnosis and treatment. She…
World’s first lung scanner to change millions of lives
Posted: 22 March 2022 Australians with lung conditions will be able to access the world’s first and only dedicated lung scanner, which was developed in Australia by BioMelbourne Network Member 4DMedical. Funded through the Morrison Government’s landmark Medical…
Imagion Biosystems: Breast cancer first-in-human study update
Posted: 18 March 2022 Imagion Biosystems Limited, a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide this update on the progress of its first-in-human study for the MagSense HER2 breast cancer…
PRAXIS: Quality Management in Research Virtual Workshop
Posted: 15 March 2022 Learn how to improve your unit processes, minimise delays, and increase the quality of your research by enrolling into PRAXIS Australia’s Quality by Design virtual workshop. On completion, you will be able to: Explain…
Our congratulations to a former intern
Posted 3 March 2022 BioMelbourne Network is fortunate to work with some passionate and capable biomedical students who join our team as interns. These interns provide much needed assistance to the organisation, while they get the opportunity to…
BioMelbourne Network Podcast
Last updated: 16 November 2022 Want to collaborate on a podcast? Reach out to us now! Episode 1: Special Visa Schemes – The Global Talent Program and Victorian State Visa Nomination Program Australia wants to attract talented people…
Stable Cell Line for Production of PAT-DX3 Established
Posted: 2 March 2022 BioMelbourne Network Member Patrys Limited, a therapeutic antibody development company, is pleased to announce it has identified and selected an optimised stable cell line for production of its full-sized IgG deoxymab, PAT-DX3. This allows…
Andrew Wear appointed to BioMelbourne Network Board of Directors
Posted: 25 February 2022 BioMelbourne Network is excited to announce the appointment of Andrew Wear as a Director on its Board of Directors as of February 2022. “I’m really excited to be joining the board. Melbourne has genuinely…
ENA Respiratory and COPD Foundation to Develop Pan-Antiviral Nasal Spray
Posted: 24 February 2022 ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19 in populations at-risk of complications, and the COPD Foundation, a…
AusBiotech greets the patent box legislation
Posted: 23 February 2022 AusBiotech has welcomed the patent box legislation that was introduced to the Australian Parliament on 10 February – to provide a tax incentive for Australian medical innovations. AusBiotech CEO, Lorraine Chiroiu, said, “AusBiotech notes…
